Skinvisible inks licensing pact with Women’s Choice Pharmaceuticals

Skinvisible concluded the development phase for the hemorrhoid formulation using Skinvisible’s technology Invisicare, a patented polymer delivery system for topical dermatology and consumer goods products.

The product has been formulated with the active ingredients hydrocortisone acetate and pramoxine hydrochloride.

Under the terms of the agreement, Skinvisible and Womens Choice Pharmaceuticals will now enter into the second phase of the agreement which grants the exclusive rights to commercialize the product within the US.

The agreement includes a license fee paid in milestones plus on-going royalties based on product sales. The product will be launched as a prescription product focused on the women’s health market.

This exclusive license expands Womens Choice’s product line which will be launched at the beginning of the second quarter of 2011.

Skinvisible president and CEO Terry Howlett said that this is another important step for Skinvisible as they now have several ongoing agreements for prescription products and continued interest for additional products both in the US and internationally.

"This recent development illustrates the versatility of Skinvisible’s Invisicare technology which provides patent-protected products not only in dermatology but other markets where topical products are sold," Howlett said.